5 November 2020

Viking Global Investors and General Atlantic invest in Pharvaris Series C funding round

Maarten van der Weijden
Joost Rendering
Bernard Spoor

De Brauw advised Viking Global Investors and General Atlantic on their investment in the Pharvaris Series C funding round.


Pharvaris is a clinical-stage biopharmaceutical company focused on developing an oral therapy for Hereditary Angioedema, which is a rare and potentially life-threatening genetic condition.